Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES LONG-TERM EXTENSION OF CATHEJELL(TM) AGREEMENT

BioSyent Inc.'s wholly owned subsidiary, BioSyent Pharma Inc., has extended its licence, distribution and supply agreement with its European partner for the Cathejell product, extending BioSyent Pharma's exclusive Canadian rights to Cathejell until 2034.

"We have had considerable success with Cathejell since launching this product in Canada in 2012," commented Rene Goehrum, president and chief executive officer of BioSyent. "Cathejell has been a consistent contributor to our specialty products portfolio and we look forward to continuing to serve our hospital and urology customers over the long-term with this trusted product."

About BioSyent Inc.

BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

We seek Safe Harbor.